The effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease: a meta-analysis of randomized controlled trials

Atherosclerosis. 2014 Jul;235(1):31-5. doi: 10.1016/j.atherosclerosis.2014.03.032. Epub 2014 Apr 18.

Abstract

Objective: High level of homocysteine induces injury of endothelial cells and predicts adverse cardiovascular events. The objective was to assess the effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease.

Methods and results: We conducted a meta-analysis of randomized controlled trials identified from PubMed, Embase, the Cochrane Library. Eight studies were included. Homocysteine-lowering therapy with folic acid in patients with coronary artery disease significantly improve FMD as compared with placebo using random-effect model (SMD = 1.65 with 95% CI 1.12-2.17, p < 0.001). Subgroup analysis of subjects revealed that lipid-lowering therapy, study duration, and Delphi criteria had no effects on FMD.

Conclusion: Our meta-analysis demonstrated that folic acid supplementation can significantly improve endothelial dysfunction as assessed by FMD in the brachial artery in patients with coronary heart disease.

Keywords: Flow-mediated vasodilation; Folic acid; Homocysteine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Atherosclerosis / drug therapy
  • Atherosclerosis / physiopathology
  • Brachial Artery / pathology
  • Coronary Artery Disease / drug therapy*
  • Dietary Supplements
  • Endothelium, Vascular / pathology
  • Female
  • Folic Acid / therapeutic use*
  • Homocysteine / blood*
  • Homocysteine / chemistry
  • Humans
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Vasodilation

Substances

  • Homocysteine
  • Folic Acid